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Metastatic uveal melanoma (mUM) is an advanced ocular malignancy
characterized by a hepatotropic pattern of spread. As the incidence of brain
metastases (BM) in mUM patients has been thought to be low, routine CNS
surveillance has not been recommended. Notably, no formal assessment of BM
incidence in mUM has to date been published to support this clinical practice.
We aimed to determine the true rate of BM in mUM and to clarify the clinical
and genomic risk factors associated with BM patients through a collaborative
multicenter, retrospective research effort. Data collected from 1,845 mUM
patients in databases across four NCI-designated comprehensive cancer
centers from 2006-2021 were retrospectively analyzed to identify patients
with BM. Brain imaging in most cases were performed due to onset of
neurological symptoms and not for routine surveillance. An analysis of
demographics, therapies, gene expression proﬁle, tumor next generation
sequencing (NGS) data, time to metastasis (brain or other), and survival in the
BM cohort was completed. 116/1,845 (6.3%) mUM patients were identiﬁed with
BM. The median age at time of UM diagnosis was 54 years old (range: 18-77).
The median time to any metastasis was 4.2 years (range: 0-30.8). The most
common initial metastatic site was the liver (75.9%). 15/116 (12.9%) BM patients
presented with BM at the time of initial metastatic diagnosis. Median survival
after a diagnosis of BM was 7.6 months (range: 0.4-73.9). The median number
of organs involved at time of BM diagnosis was 3 (range: 1-9). DecisionDX-UM
proﬁling was completed on 13 patients: 10-Class 2, 2-Class 1B, and 1-Class 1A.
NGS and cytogenetic data were available for 34 and 21 patients, respectively.
BM was identiﬁed in 6.3% of mUM cases and was associated with high disease
burden and a median survival of under 8 months once diagnosed. Since most
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patients in this cohort were symptomatic, the incidence of asymptomatic BM
remains unknown. These data suggest the use of routine brain imaging in all
mUM patients at risk for developing BM for early detection.
KEYWORDS

uveal melanoma, brain metastases, cutaneous melanoma, mucosal melanoma, acral
melanoma, ocular oncology

Introduction

location, extraocular extension, and ciliary body involvement.
These components were utilized to generate UM staging which
increase the 10-year risk of metastasis twofold with each stage.
UM thickness in particular has been shown to be an important
prognostic factor. Small thickness UM (0-3 mm in thickness)
was associated with a 5- and 10-year metastatic risk of 6% and
12%. The 5-/10-year metastatic risk of medium thickness (3.18 mm) and large tumors (>8 mm in thickness) was 14%/26% and
35%/49%, respectively (9). Regarding genomic factors,
cytogenetic and next generation sequencing-based assays are
used to classify metastatic risk. In particular, gene expression
proﬁling (GEP) is a validated method to estimate metastatic risk
and categorizes primary UM tumors as Class 1A, Class 1B, and
Class 2 disease. Class 1 is divided into two groups: 1A (favorablerisk) and 1B (intermediate-risk) (20). Class 1A GEP tumors
carry a main secondary mutation in EIF1AX and have 2 sets of
chromosome 8q and partial or total gain of chromosome 6p
while class 1B GEP tumors are SF3B1-mutated and have a partial
gain of 8q or gain of 6p (21, 22). Class 1A is associated with
lower metastatic potential compared to Class 1B with a 5-year
metastatic risk of 2% vs 21% (23). Class 2 GEP (high-risk) is
characterized by BAP1 loss with cytogenetic aberrations
including monosomy 3 or multiple copies of chromosome 8q
(24). Class 2 disease is associated with a 72% risk of metastatic
disease at 5 years (25).

Uveal melanoma (UM) is a rare ocular cancer which arises in
over 90% of cases from choroidal melanocytes (1). Pigmented
cells within the ciliary body (6%) and the iris (4%) can also
develop into UM (2). It is more prevalent among males and
associated with Caucasians aged 50-70 years old (3, 4).
Prevalence around the world is highest in northern European
countries with an incidence of 8 per million (5). In the United
States, the incidence is approximately 4.6-5 per million with
rates being the highest in non-Hispanic whites (3) (6) (4). Risk
factors for UM include fair skin, light-colored eyes, northern
European ancestry, and sensitivity to sunburns (7) (8).
Approximately 50% of patients with UM will develop
metastatic disease within 10 years of primary tumor diagnosis
(9) (10). Metastatic UM (mUM) unfortunately confers a poor
prognosis of 12-15 months (11) (12) and remains with few
treatment options. In January 2022, tebentafusp was approved
by the Food and Drug Administration as the ﬁrst disease-speciﬁc
treatment for mUM patients however the therapy is restricted to
HLA-A*0201 haplotypes (13, 14). The pathogenesis of mUM is
associated with two main events: a gain of function mutation in
the Ga signaling pathway and a secondary alternation – a BAP1,
SF3B1 or EIF1AX mutation (“BSE” mutation), which are
prognostic for metastatic risk (15). Biallelic inactivation of BAP1
changes regulation in protein de-ubiquitination, cell cycle and
apoptosis (16). SF3B1 encodes for the U2 snRNP component of
the spliceosome. Mutations in SF3B1 causes abnormal splicing
leading to frameshift mutations and mRNA degradation or
alternately to activation or change of function mutation (17).
Lastly EIF1AX is thought to be a component of the 43s preinitiation complex responsible to initiate protein translation, but
its downstream effects are not completely clear (18). Targeted
therapies against downstream effectors of the aforementioned
pathways are in various stages of development (19).
In the current era, prognostication and metastatic risk
estimation in UM are based upon clinical and genetic factors.
The American Joint Committee on Cancer (AJCC) Cancer
Staging Manual (8 th Edition) includes tumor thickness,
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The pattern of metastasis in UM has been considered to be
primarily hematogenous with a marked hepatotropism.
Circulating tumor cells (CTC) and tumor DNA (ctDNA) have
both been detected in the blood of individuals with mUM (26).
However, all patients within the study had radiological signs of
metastasis and thus any measurable CTC or ctDNA may simply
be a reﬂection of tumor burden. The most common initial site of
metastasis is the liver, with up to 95% of hepatic metastases seen
during the course of mUM (10). Factors driving this
hepatotropism are not fully clariﬁed, but this phenomenon
may in part be explained by known c-MET expression by UM
and the prevalence of its associated ligand, hepatocyte growth
factor (HGF), in liver viscera (27). Hypothetically, tumor cells
can migrate through the hepatic parenchyma, occupy a
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screening brain imaging for clinical trial enrollment. The
primary objective of this study was to describe the clinical
characteristics of UM patients who develop BM. Secondary
objectives included determination of median overall survival
(mOS) from primary UM diagnosis, initial metastatic diagnosis,
and onset of brain metastasis.

periportal location, and eventually recruit factors for
angiogenesis (28). Additional frequent metastatic sites include
the lungs (31%), bones (23%) and soft tissue (17%) (29). As up to
50% of UM patients are at risk for developing metastatic disease,
surveillance imaging with abdominal magnetic resonance
imaging (MRI) has been recommended for patients with high
risk for progression, such as those with BAP1 mutations of Class
2 gene expression proﬁles (30) (31).
As the incidence of brain metastasis in UM has been
considered to be low, routine brain imaging has historically
not been recommended. To date, however, the incidence and
prevalence of brain metastases (BM) in UM have never been
described. All aforementioned prognosticating methodologies
include the risk of liver, lung, and bone metastases but do not
take BM into account due to limited data availability. BM are
believed to be rare, however the clinical characteristics and
underlying tumor biology of mUM patients with BM have
never been described.

Statistical analysis
Variables, both continuous and categorical, were
summarized with descriptive statistics.

Results
116 out of 1,845 patients with metastatic uveal melanoma
(mUM) developed BM (6.3%) (Table 1). Brain imaging was
obtained only upon onset of neurological symptoms in most
cases of identiﬁed brain metastases and not for asymptomatic
surveillance. The median age at time of UM diagnosis was 54
years old (range: 18-77). A slight majority of cases occurred in
females (54.3%). 89.7% of patients were Caucasian, 4.3% were
non-Caucasian, and 6.0% did not report their ethnicities. The
majority of primary tumors arose within the choroid (95.2%)
followed by iridociliary bodies (2.9%) and the iris (1.9%). Twelve
patients did not have initial tumor site location known.
No patients were diagnosed with BM at the time of diagnosis
of the primary tumor, although 1 patient did present with nonBM metastatic disease. The median time to recurrence to mUM
was 4.2 years (range: 0-30.8; Figure 1A) while the median time to
development of BM from primary diagnosis was 6.5 years
(range: 0.04-32.8; Figure 1B). The median time to
development of BM from initial mUM diagnosis was 1.2 years
(range: 0-9.6; Figure 1C).
An analysis was completed to evaluate the pattern of
spread in mUM. At time of mUM diagnosis, the most
common site of metastasis was the liver (75.9%, n=88)
followed by bone (18.1%, n=21), the lungs (17.2%, n=20),
soft tissue (12.9%, n=15), and brain (12.9%, n=15) (Figure 2).
The median number of organ systems involved with tumor was
3 (range: 0-9) at the time of BM. Serum LDH was measured in
86 patients with BM and was elevated in 65.1% of patients
(25.6% > 1X ULN and 39.5% >2X ULN).
At time of data cutoff, 84.8% of patients were deceased
(n=95). mOS from primary diagnosis and initial mUM
presentation for this cohort were 8.6 years (range: 0.2-38.4)
and 2.2 years (range: 0.2-14.1), respectively (Figures 3A, B).
Following diagnosis of symptomatic BM, mOS was 7.6 months
(range: 0.4-73.9; Figure 3C).
DecisionDX-UM gene expression proﬁling (GEP) was
completed on the primary tumors of 13 patients who

Materials and methods
Patients
Deidentiﬁed medical data from 2006-2021 were extracted
from medical center databases following institutional review
board approval. UM patient records were reviewed for the
presence of brain metastases (BM) diagnosed at any point in
the disease course through MRI scans. Four NCI-designated
comprehensive cancer centers within the United States
participated in this study in order to create a large, real-world
data set for a rare cancer. The secure, institutional databases
queried included consecutive patient data at Columbia
University, Thomas Jefferson University, Memorial Sloan
Kettering Cancer Center, and the Dana-Farber Cancer Institute.

Study design
Data including patient demographics (gender, age,
ethnicity), tumor characteristics (primary site, primary tumor
gene expression proﬁle, initial metastatic site, location of
metastases, presence of brain metastases, serum lactate
dehydrogenase (LDH) level, immunohistochemistry,
cytogenetics, metastatic tumor next generation sequencing),
treatment history (immunotherapy exposure, lines of therapy),
and outcomes (date of primary diagnosis, metastatic diagnosis,
and ﬁrst brain metastasis) were obtained. Brain imaging in
almost all cases were performed due to the onset of
neurological symptoms and not for routine surveillance.
Asymptomatic patients were otherwise detected due to
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TABLE 1 Clinical characteristics of uveal melanoma patients with brain metastases.

Demographics (n=116)
Age, median (range)

54 (range: 18-77)

Female (%)

63 (54.3%)

Primary Tumor Site (n=104)
Choroid

99 (95.2%)

Iridociliary bodies

3 (2.9%)

Iris

2 (1.9%)

Initial Site of Metastases in Patients Who Develop Brain Metastases (n=116)
Liver

88 (75.9%)

Bone

21 (18.1%)

Lungs

20 (17.2%)

Brain

15 (12.9%)

Soft tissue

15 (12.9%)

Lymph node

8 (6.9%)

Adrenals

4 (3.4%)

Other organs involved at time of symptomatic brain metastasis, median (range)

3 (range: 0-9)

Serum Lactate Dehydrogenase at Time of Brain Metastasis (n=86)
Normal

30 (34.9%)

>1 ULN (%)

22 (25.6%)

>2 ULN (%)

34 (39.5%)

Elevated LDH (%)

56 (65.1%)

Treatment (n=114)
Lines of therapy prior to brain metastasis, median (range)

3 (range: 0-10)

Treatment with ICI prior to brain metastasis (%)

64 (56.1%)

Cytogenetics (n=21)
Monosomy 3 or 3p deletion (%)

15 (71.4%)

8q ampliﬁcation (%)

14 (66.67%)

Gene expression proﬁle by DecisionDX-UM (n=13)
Class 1A (%)

1 (7.7%)

Class 1B (%)

2 (15.4%)

Class 2 (%0

10 (76.9%)

Mutations by Targeted Molecular Panels and Immunohistochemistry
BAP1 (n=33)

20 (60.6%)

SF3B1 (n=22)

10 (31.3%)

EIF1AX (n=32)

1 (4.5%)

Mutations by Next Generation Sequencing (n=34)
GNAQ/GNA11

24 (70.1%)

BAP1

5 (14.7%)

PRKCE

4 (11.8%)

MET

4 (11.8%)

CDK2

3 (8.8%)

BCL2

3 (8.8%)

CDKN2A

3 (8.8%)

BRAF

2 (5.9%)

SF3B1

2 (5.9%)

EIF1AX

1 (2.9%)

Table 1 describes the clinical characteristics of uveal melanoma patients who develop brain metastases at any point during their disease course. LDH, lactate dehydrogenase. ULN, upper
limit of normal. ICI, immune checkpoint inhibitor (Anti-PD1, Anti-PD-L1, Anti-CTLA4).
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A
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FIGURE 1

Recurrence Free Survival Kaplan-Meier survival plots representing (A) recurrence free survival from primary diagnosis (median 4.2 years, range:
0-30.8), (B) development of brain metastasis from primary UM diagnosis (6.5 years, range: 0.04-32.8), and (C) development of brain metastasis
from initial metastatic UM diagnosis (1.2 years, range: 0-9.6). N = 116.

Previous treatment data from mUM patients with BM were
reviewed. Patients received a median of 3 lines of systemic therapy
(range: 0-10) prior to developing symptomatic BM. Therapies
included both FDA-approved and clinical trial agents. 56.1% of
patients received immune checkpoint inhibitors, either as singleor dual agents, prior to BM.

eventually developed BM. 10 patients were found to have Class 2
disease. BAP1, SF3B1, and EIF1AX mutations were detected by
immunohistochemistry in 20 out of 33 (60.6%), 10 out of 32
(31.3%), and 1 out of 22 (4.5%) cases respectively. Cytogenetic
analysis was available for 21 patients with BM. Monosomy 3 or
3p deletion was detected in 15 samples while chromosome 8q
was ampliﬁed in 14 cases. Including the former cases, 11 tumor
samples had both monosomy 3/3p deletion and 8q
ampliﬁcation. NGS was completed on 34 metastatic tumor
samples. 24 of 34 patients (70.6%) had detectable GNAQ/
GNA11 mutations. The most notable common non-GNAQ/
GNA11 mutations were BAP1 (n=5, 14.7%), MET (n=4, 11.8%),
PRKC (n=4, 11.8%), CDK2 (n=3. 8.8%), CDKN2A (n=3, 8.8%),
SF3B1 (n=2, 5.9%), and BRAF (n=2, 5.9%) variants.

Frontiers in Oncology

Discussion
Brain metastases in uveal melanoma are not rare despite
prior beliefs. Although no patients in our cohort were diagnosed
with BM on initial primary diagnosis, 6.3% of mUM patients
ultimately developed BM. Furthermore, nearly 13% of mUM
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FIGURE 2

Pattern of initial UM metastasis in patients with brain metastases (n = 116) Figure 2 describes anatomical locations involved at time of initial
metastatic diagnosis in our described cohort. Both oligometastatic and synchronous metastatic presentations were observed. The initial site(s)
of metastatic disease were liver (n = 88, 75.9%), bone (n = 21, 18.1%), lungs (n = 20, 17.2%), soft tissue (n = 15, 12.9%), brain (n = 15, 12.9%),
lymph nodes (n = 8, 6.9%), and adrenals (n = 4, 3.4%).

patients, the majority of these patients had Class 2 disease,
however a bigger sample use will be required to draw any
further conclusions about the utility of UM gene expression
proﬁling in predicting BM. Similarly, drawing conclusions from
NGS data proved challenging as there remains no accepted,
standardized assay for sequencing UM samples. For instance,
only 71% of patients had GNAQ/GNA11 mutations detected
however it is well known that these mutations are observed in
over 90% of UM cases (33), which suggests that these genes may
not have been routinely investigated for. Cytogenetic analysis
suggested that the majority of patients with BM had either loss of
chromosome 3 or chromosome q8 ampliﬁcation, which are both
underlying defects associated with metastatic UM (34, 35).
Given the paucity of data in this setting, exploring the
genomic and molecular underpinnings of BM development in
UM remains an area in need of further investigation.
Our results prompted a comparison to previously described
mechanisms and rates of BM development in cutaneous (CM),
mucosal (MM), and acral melanomas (AM) (Table 2). Multiple
studies have reported an incidence of BM in 10% of CM patients,
while 40-80% of patients with metastatic CM will develop BM
(36, 43). Common risk factors include male gender, age >60,
invasive or ulcerated lesions, elevated LDH, and visceral
metastasis (44). The development of BM in CM has been
strongly associated with the loss of PTEN expression, which
leads to increased activation of the PI3K-AKT pathway (45).
JAK-STAT signaling and VEGF-A may also play a role in BM
development given their effects on blood-brain-barrier
permeability and cell growth (46, 47). Additionally, PLEKHA5,
which is implicated in brain development, has been implicated
as a possible promoter of BM (48). The majority of CM

patients who ultimately developed BM presented with BM at
time of metastatic diagnosis. The discovery of BM was associated
with a poor prognosis of less than 8 months. BM appear to be a
late stage of mUM as represented by multi-organ disease
involvement at time of diagnosis. Additionally, half of patients
had already received multiple lines of systemic therapy,
including immune checkpoint inhibitor therapy. As only
symptomatic mUM patients were included in this study, the
true incidence of BM including asymptomatic patients remains
unknown, but is likely higher.
The demographic data from our cohort closely resemble
previously reported characteristics (32). The vast majority of
UM patients were Caucasian with primary tumors that arose
from the choroid. In the metastatic setting, most patients
experienced a hepatotropic spread of their cancer. The time
course, however, was more varied and represented a more
heterogenous disease. The wide range of time between primary
and metastatic diagnoses suggest inclusion of patients with
deleterious BAP1 mutations associated with an aggressive
disease, SF3B1 mutations with late metastatic potential, and
other genetic and epigenetic variants which remain unclariﬁed.
The mOS for patients with mUM was roughly 2 years, which is
longer than purported survival length of 15 months; however,
this cohort of patients was enriched for those with later stages
of disease.
We attempted to extract genomic data of interest from
mUM with BM. Despite multicenter representation, GEP,
tumor NGS, and cytogenetics data were only available for 13,
34, and 21 patients, respectively, likely due to their relative
novelty and/or accessibility. DecisionDx-UM GEP was available
in 2017 and only began widespread use in 2019. Of these 13
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FIGURE 3

Depicts the median overall survival from (A) time of primary diagnosis (8.6 years, range: 0.2-38.4), (B) time of initial metastatic disease (2.2 years,
range: 0.2-14.1), and (C) time of brain metastasis diagnosis (7.6 months, range: 0.4-73.9). N = 116.
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TABLE 2 Brain metastases across melanoma subtypes.

CM

UM

MM

AM

Incidence of BM in metastatic patients

40-60% (36)

6.3%

20-50% (37)

30% (38)

Incidence of BM on initial metastatic diagnosis

30-40% (39)

12.9%

9.2% (40)

Unknown

mOS from BM diagnosis (months)

4-6 (41, 42)

7.6

Unknown

Unknown

Most common initial site of metastasis

Lymph node

Liver

Lymph node

Lymph node

Table 2 compares the pattern of brain metastases and initial metastases across different melanoma subtypes. CM, cutaneous melanoma; UM, uveal melanoma; MM, mucosal melanoma;
AM, acral melanoma.

subsequently. Patients with late stages of disease, including 3 or
more visceral metastases, a mUM diagnosis over 14 months
prior, or treatment failure after 3 systemic lines of therapy
should be strongly considered for surveillance brain imaging.
Since mUM treatment is currently palliative in intent, an
intracranial lesion detected and treated early with regional
therapies, including stereotactic radiosurgery (50), could
prevent future neurological symptoms and improve quality of
life. Future directions of this study include clarifying the
underlying molecular mechanisms for the development of BM
in UM through tumor whole exome/genome sequencing and, if
routine brain imaging occurs, incorporating patients with
asymptomatic BM to measure the true incidence of BM in UM.

metastases are found in regional lymph nodes; however,
common distant metastatic sites include the liver and lungs.
This pattern of spread differs signiﬁcantly from UM where all
metastases are typically distant and hepatotropic. Despite this
difference, PTEN and other effectors of the PI3K-AKT, JAKSTAT, and VEGF-A signaling pathways should be further
investigated as possible underlying mechanisms behind BM in
UM. From a clinical perspective, the presence of BM in CM is
associated with a poor prognosis of 4-6 months (41), which
suggests a more aggressive course when compared to the uveal
counterpart described in our report.
There is limited literature describing the incidence of BM in
MM. Furthermore, there is likely signiﬁcant heterogeneity in
MM depending on the site of anatomical origin (49). A
multicenter, retrospective study from France described 21 out
of 229 metastatic MM patients (9.2%) had BM at ﬁrst treatment
(40). No data was available describing whether these were oligo-,
synchronous, or metasynchronous metastases. A single
prospective study of 706 patients describes a metastatic pattern
involving a predilection for regional lymphatic (21.5%),
pulmonary (21%), and hepatic (18.5%) tissues. No patients
with metastatic BM were described. The WHO estimates that
the incidence of BM in MM is between 20-50% however this has
never been conﬁrmed clinically (37). There is no data regarding
molecular markers associated with BM or AM in MM. AM is
another rare subset of melanoma with metastatic data equally
scarce. One study of 67 metastatic patients (38) described a
lymphatic pattern of spread with 94% of patients (n=63)
presenting with nodal disease. At time of last follow-up
(n=40), 75% of patients (n=30) had developed pulmonary
disease followed closely by hepatic (62.5%, n=25) and bone
(55%, n=22) involvement. BM was reported in 12
patients (30%).
Given our ﬁnding that BM in UM is not uncommon, with
6.3% of mUM patients developing BM and 12.9% of those
patients presenting with symptomatic BM at time of
metastatic diagnosis, an argument can be made to recommend
routine surveillance brain imaging for all patients with UM at
the time of initial metastatic diagnosis and at periodic intervals
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